LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

ABBOTT PARK, Ill., Jan. 2, 2025 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens.  The announcement will be followed by a live webcast of the earnings conference call at 8:30 a.m. Central time (9:30 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics,

MISSISSAUGA, ON, Dec. 17, 2024 /CNW/ -- Abbott (NYSE:ABT) today announced that the Government of Alberta has added Abbott's FreeStyle Libre 2* flash glucose monitoring system to the Alberta Drug Benefit List. Starting December 16, 2024, Alberta residents living with diabetes can access provincial reimbursement of the FreeStyle Libre 2 system if they are 18 or older and are being treated with insulin pump therapy, both basal and bolus insulin, or premixed insulin. People under the age of 18 can access the FreeStyle Libre 2 flash glucose monitoring system* if they use any type of insulin. "This is important news for Albertans living with diabetes," said Jeff Winterstein, M.D., an Edmonton-bas

Abbott's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left bundle branch area, activating the heart's natural conduction systemThe device has received U.S. Food and Drug Administration Breakthrough Device Designation, which expedites the review of innovative technologiesBy creating a new pacing approach for the left bundle branch area of the heart, Abbott continues to pursue technologies to revolutionize care for people with slow or irregular heart rhythmsABBOTT PARK, Ill., Dec. 17, 2024 ­­­/PRNewswire/ -- Abbott (NYSE:ABT) today announced the successful completion of the world's first in-human leadless left

Dividend increased by 7.3%Quarterly dividend payout has increased more than 60% since 2020404th consecutive quarterly dividend to be paid by Abbott since 1924ABBOTT PARK, Ill., Dec. 13, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced that its board of directors has increased the company's quarterly common dividend to 59 cents per share, an increase of 7.3%. The company's quarterly dividend payout has increased more than 60% since 2020. This marks Abbott's 53rd consecutive year of dividend growth. It will be the 404th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Feb. 14, 2025, to shareholders of record at the close of business on Jan. 15

Nearly 20,000 Big Ten students, alumni and fans across the country donated blood as part of the Abbott-Big Ten nationwide competition this college football season, helping save as many as 60,000 livesNebraska's win was announced at the Discover Big Ten Football Championship Game where the university received $1 million from global healthcare company Abbott to advance student and community healthThe competition, which will be back next fall, aims to help combat the greatest need for blood in a generation, while also helping create new lifelong blood donorsABBOTT PARK, Ill., and INDIANAPOLIS, Dec. 7, 2024 /PRNewswire/ -- This college football season, Abbott (NYSE:ABT) and the Big Ten put fando

MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE:ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his

The investigational transcatheter aortic valve implantation (TAVI) system will complement Abbott's Navitor™ TAVI system for aortic stenosis, a common and life-threatening heart valve diseaseThe investigational system is designed to offer best-in-class heart blood flow, ease of use and precisionApproximately 9% of older Americans have aortic stenosis1ABBOTT PARK, Ill., Nov. 25, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward Abbott's software-guided

Canadians living with type 2 diabetes agree that uplifting words, positive feedback and supportive tools are the most powerful motivatorsMISSISSAUGA, ON, Oct. 30, 2024 /CNW/ -- Abbott (NYSE:ABT) today released new data highlighting the emotional challenges faced by people living with type 2 diabetes, revealing key motivators to help them manage their condition. Nearly 12 million Canadians are living with diabetes or pre-diabetes, and the overwhelming majority have or will be diagnosed with type 2.1 While a variety of factors contribute to the risk of developing type 2 diabetes

Tidepool partners with Abbott for seamless data integration, expanding patient choice, and streamlining diabetes care workflows. Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce a new data integration partnership with continuous glucose monitoring (CGM) manufacturer Abbott (NYSE:ABT). A major development towards the goal of patient and provider choice, the cloud-to-cloud integration will provide a continuous, automatic stream of data from patients using FreeStyle Libre CGM to Tidepool+. Tidepool+, a diabetes data visualization and population health platform, provides intuitive tracking and visualization of diabetes data making the data

For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime

4 - ABBOTT LABORATORIES (0000001800) (Issuer)

4 - ABBOTT LABORATORIES (0000001800) (Issuer)

4 - ABBOTT LABORATORIES (0000001800) (Issuer)

4 - ABBOTT LABORATORIES (0000001800) (Issuer)

4 - ABBOTT LABORATORIES (0000001800) (Issuer)

4 - ABBOTT LABORATORIES (0000001800) (Issuer)

4 - ABBOTT LABORATORIES (0000001800) (Issuer)

4 - ABBOTT LABORATORIES (0000001800) (Issuer)

4 - ABBOTT LABORATORIES (0000001800) (Issuer)

4 - ABBOTT LABORATORIES (0000001800) (Issuer)

Oppenheimer initiated coverage of Abbott Labs with a rating of Outperform and set a new price target of $130.00

Piper Sandler initiated coverage of Abbott Labs with a rating of Overweight and set a new price target of $131.00

Edward Jones downgraded Abbott Labs from Buy to Hold

Goldman initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $121.00

Wolfe Research upgraded Abbott Labs from Underperform to Peer Perform

Morgan Stanley downgraded Abbott Labs from Overweight to Equal-Weight and set a new price target of $112.00

Barclays reiterated coverage of Abbott Labs with a rating of Overweight and set a new price target of $127.00 from $125.00 previously

Wolfe Research reiterated coverage of Abbott Labs with a rating of Underperform and set a new price target of $103.00 from $107.00 previously

Bernstein reiterated coverage of Abbott Labs with a rating of Outperform and set a new price target of $133.00 from $132.00 previously

JP Morgan reiterated coverage of Abbott Labs with a rating of Overweight and set a new price target of $122.00 from $118.00 previously

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE:ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his

PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the appointment of Catherine Mazzacco to its Board of Directors. "I am pleased to welcome Catherine to our Board of Directors at this crucial next stage of Krystal's evolution," said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech, Inc. "As a seasoned executive with extensive valuable pharmaceutical and biotechnology industry experience, I look forward to Catherine's involvement and assistance in guiding our strategic objectives." "A

Westport, CT, March 16, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the appointment of John Sieckhaus as Chief Operating Officer. Mr. Sieckhaus brings to the Company 30 years in the healthcare industry, including 21 years at St. Jude Medical and Abbott Laboratories (NYSE:ABT). During his tenure with St. Jude Medical, Mr. Sieckhaus held commercial leadership positions of rising responsibility, including U.S. National Sales Leader, Senior Vice P

LOS ANGELES, Jan. 11, 2022 /PRNewswire/ -- ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief operating officer (COO). In this role, Ms. Gloria will oversee business operations across the company. A former oncology nurse, Ms. Gloria has two decades' experience in the biotechnology industry having led a variety of research and development (R&D

NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Dr. Anthony Yeh to the position of Chief Strategy Officer and Head of China business development (BD), where he will lead corporate strategy, China BD, and capital fundraising. He will report to Dr. Mingjiu Chen, Chief Executive Officer (CEO). Prior to joining Biosion, Dr. Yeh was most recently Vice President, Head of Corporate Strategy, Investor Relations and Capital Market at CStone Pharmaceuticals (HKSE:2616). "We are pleased to welcome Anthony to Biosion as we continue to expand globally and strengthen our executive le

ABBOTT PARK, Ill., Dec. 10, 2021 /PRNewswire/ -- Abbott (NYSE:ABT) announced that its Board of Directors has elected Chief Executive Officer Robert B. Ford as Chairman of the Board, effective today. Miles D. White, executive chairman and former CEO, will step down from the Abbott Board effective today and will retire after a remarkable 38-year career with the Company. "We're grateful for Miles' leadership and his exceptional work to transform Abbott into the leading health technology company that it is today," said William A. Osborn, lead director and chair of the Nominations and Governance committee. "Robert has continued to strengthen Abbott's position by advancing our industry-leading pip

PITTSBURGH, Dec. 02, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the appointment of Curt Bradshaw, Ph.D., as its new Chief Scientific Officer. Dr. Bradshaw is a proven drug developer in the field of precision genetic medicines, coming to NeuBase from his most recent role as Chief Scientific Officer at Arrowhead Pharmaceuticals. In his new role, Dr. Bradshaw will be responsible for leading and expanding NeuBase’s PATrOL-enabled anti-gene pipeline and will serve as a key member of its executive management team. “